Table 2.

Clinical and imaging data for different phases of the study. P values are provided for each component

	Pre-intervention	Interim-intervention	Post-intervention	P
Number	14	39	45
Age, mean ± SD	61.57	66.87	65.29	0.434
Male, n, %	11 (78.6%)	30 (76.9%)	31 (68.9%)	0.643
Hypertension, n, %	6 (42.9%)	24 (61.5%)	30 (66.7%)	0.679
AF, n, %	6 (42.9%)	13 (33.3%)	17 (37.8%)	0.802
DM, n, %	1 (7.1%)	6 (15.4%)	11 (24.4%)	0.284
CAD, n, %	4 (28.6%)	9 (23.1%)	9 (20.0%)	0.792
Previous Stroke, n, %	1 (7.1%)	10 (25.6%)	9 (20.0%)	0.336
Dyslipidemia, n, %,	1 (7.1%)	5 (12.8%)	9 (20.0%)	0.434
CKD, n, %	0 (0.0%)	3 (7.7%)	7 (15.6%)	0.193
Smoker, n, %	7 (50.0%)	12 (30.8%)	9 (20.0%)	0.088
mRS pre-treatment (IQR)	0.0 (0.0,0.0)	0.0 (0.0,0.0)	0.0 (0.0,0.0)	0.597
pre-treatment ASPECTS (IQR)	9.0 (8.0,9.0)	8.0 (8.0,9.0)	8.0 (7.5,9.0)	0.184
Admission NIHSS (IQR)	19.0 (11.0,21.0)	14.0 (11.0,18.0)	17.0 (14.0,21.0)	0.026
Vessels occlusion
ICA, n, %	2 (14.3%)	8 (20.5%)	6 (13.3%)	0.697
M1, n, %	5 (35.7%)	16 (41.0%)	22 (48.9%)
M2, n, %	0 (0.0%)	1 (2.6%)	0 (0.0%)
Basilar artery, n, %	5 (35.7%)	8 (20.5%)	14 (31.1%)
Tandem, n, %	2 (14.3%)	6 (15.4%)	3 (6.67%)
TOAST type
LAA, n, %	3 (21.4%)	22 (56.4%)	19 (42.2%)	0.028
CE, n, %	6 (42.9%)	15 (38.5%)	22 (51.2%)
SVO, n, %	0 (0.0%)	1 (2.6%)	0 (0.0%)
SOE, n, %	3 (21.4%)	0 (0.0%)	2 (4.4%)
SUE, n, %	2 (14.3%)	1 (2.6%)	2 (4.4%)
IV Thrombolysis, n, %	7 (50.0%)	18 (46.2%)	23 (51.1%)	0.942

Abbreviations – AF Atrial fibrillation, DM Diabetes mellitus, CKD Chronic kidney disease, CAD Coronary heart disease, ICA Internal carotid artery, IV Intravenous, LAA Large-artery atherosclerosis, CE Cardioembolism, SOE Stroke of undetermined etiology, SUE Stroke of undetermined etiology, SVO Small vessel occlusion